Dope Entrepreneurs
  • Research
  • News
  • Interviews
  • Articles
  • Reviews
No Result
View All Result
  • Research
  • News
  • Interviews
  • Articles
  • Reviews
No Result
View All Result
Dope Entrepreneurs
No Result
View All Result
Home Research

“IBS Patients Are Willing To Accept Significant Risks In Return For Cure Of IBS Symptoms” – A Recent UK Study

IBS sufferers ready to accept any risk necessary for relief and cure.

hplictawa@gmail.com' by Editorial Team
May 7, 2022
in Research
0
“IBS Patients Are Willing To Accept Significant Risks In Return For Cure Of IBS Symptoms” – A Recent UK Study
2.8k
SHARES
6.3k
VIEWS
Share on FacebookShare on TwitterShare On Whatsapp

Medically reviewed by Onikepe Adegbola, MD, PhD

IBS Treatment and Risks

Irritable bowel syndrome (IBS) patients are prepared to adopt therapies that pose major risks to permanently heal their symptoms, according to experts from Leeds, UK.

ADVERTISEMENT

The main finding of this study was that participants of this study would, on average, accept a 2.0% risk of death for a 98.0% chance of permanent cure of IBS symptoms. Moreover, male participants and participants with severe symptoms, psychiatric comorbidities, a history of using multiple treatments in the last 12 months, or poor quality of life were ready to accept a higher risk of death of up to 5% in exchange for a permanent cure of their symptoms.

The above findings are from a study titled “Willingness to accept risk with medication in return for the cure of symptoms among patients with Rome IV irritable bowel syndrome,” which was recently published in Alimentary Pharmacology & Therapeutics. This study analyzed the data of 752 adult patients with Rome IV-IBS. 

Why is this study important?

This study offers patient perspectives on the risks associated with medical treatments. The decision-makers regarding the licensing of medical treatments are mostly experts. Experts sitting in the regulatory bodies may not license medical treatments due to the inherent risks.

New medical treatments may be rejected or delayed by experts despite strong willingness in the patients to accept the reasonable risk of severe complications, including death. Studies like these can present the experts with valuable insights from patients, which they can consider when making licensing decisions for medical treatments.

The authors of this study point out that earlier studies have also shown a strong willingness among patients with IBS to accept risks. But those were small-scale studies conducted on selected patients and used ROME III diagnostic criteria, which are no longer relevant. Thus, the earlier studies could not be generalized. 

Alternatively, this study has a fairly decent sample size of 752 patients and uses the ROME IV criteria for diagnosis. Additionally, unlike the previous studies, this study recruited patients from the community, and 80% of the participants have had IBS for over 5 years. Thus, the authors highlighted that this study may be a more valid assessment of what’s going on in the minds of patients with IBS. But, this study was mainly conducted on patients of White ethnicity residing in the UK, and it may not apply to other populations.

What are the key takeaways from this study?

This study shines a light on the impact of IBS on the psyche of patients. They are willing to accept sufficiently high risks to achieve a cure for their symptoms. Furthermore, people with IBS who have more severe symptoms and a lower quality of life are prepared to take on additional risks in return for a cure. Thus, this study reinforces the need for effective treatments for IBS, which is an important concern alike for regulators, pharmaceutical companies, and physicians.

Reference:

Goodoory, V. C., Ng, C. E., Black, C. J., & Ford, A. C. (2022). Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndrome. Alimentary pharmacology & therapeutics, 55(10), 1311–1319. https://doi.org/10.1111/apt.16816

Tags: IBSibs risksibs treatment
hplictawa@gmail.com'

Editorial Team

Related Posts

A research paper was published in the Brazilian Journal of Biology, titled "Using Bifidobacterium and Propionibacterium Strains in Probiotic Consortia to Normalize the Gastrointestinal Tract." Based on expert opinions in the study, the microorganisms Bifidobacterium and Propionibacterium genera qualities can be preserved and encapsulated. This research backs up expert suggestions with clinical evidence, proving that the experts were correct. The gut microflora is responsible for regulating the body's activities and maintaining its health. Diabetes, obesity, inflammation, atherosclerosis, and other chronic diseases are due to dysbiosis. In the 2024 recommendations, experts recommended probiotics for living microorganisms that benefit the microflora and improve the health of the host organism helping prevent these diseases. Lactic acid bacteria from the Bifidobacterium and Propionibacterium genera are the frequent probiotics recommended. Bifidobacterium adolescentis-1909, Bifidobacterium longum infantis-1912, Propionibacterium jensenii B-6085, Propionibacterium freudenreichii -11921, Propionibacterium thoenii -6082, and Propionibacterium acidipropionici-5723 were examined for their probiotic characteristics in the study. This study was conducted in the Laboratory for Bio testing Natural Nutraceuticals at Kemerovo State University (Russia). The study used collection strains of the lactic acid bacteria Bifidobacterium adolescentis АС-1909, Bifidobacterium longum infantis АС-1912, Propionibacterium jensenii В-6085, Propionibacterium freudenreichiiВ-11921, Propionibacterium thoenii В-6082, and Propionibacterium acidipropionici В-5723. Lactic acid cultures were tested for antibacterial activity against the test cultures Salmonella enterica ATCC 14028, Staphylococcus aureusATCC 25923, Pseudomonas aeruginosa B6643, Proteus Vulgaris ATCC 63, and Listeria monocytogenes ATCC 7644. Additionally, the antibiotic resistance of lactic acid cultures was tested using the disk diffusion method. Bifidobacterium adolescentis-1909, Propionibacterium jensenii B-6085, and Propionibacterium thoenii 6082 showed moderate antibacterial activities against all test cultures. According to research, some Propionibacterium and Bifidobacterium strains, or their consortia, could be employed as probiotic cultures in dietary supplements or functional foods to prevent various chronic diseases like IBS. Why is this study important for patients with IBS Symptoms Although IBS is bothersome and inconvenient, it does not increase the chance of developing other health problems. However, the success of the treatment depends on what grade of IBS it is and how it is addressed. Bifidobacterium bacteria are particularly significant compared with other gut microbiota in probiotic cultures. Probiotics have a favorable effect in four ways. First, they produce antimicrobial compounds. Second, they are hostile to pathogenic and opportunistic strains. They also adhere to epithelial cells (cells of intestinal walls), posing a competitive threat to disease-causing bacteria. Finally, they inhibit the production of metabolites by pathogenic bacteria and cancer cells. What is the Key Takeaway from this Study Large doses of probiotics that contain these bacteria in dietary supplements or functional fermented milk products can stimulate their proliferation in the large intestine. The development of functional foods containing probiotics, particularly Bifidobacterium strains, is driven by the increased demand for health-beneficial foods. However, Propionibacterium 'dairy' strains have recently gained popularity. As a result, probiotic consortia of these species can be established to normalize the gastrointestinal microbiota's function. To preserve their quality, these microorganisms can be encapsulated (immobilized). All the strains can be employed to form various dietary supplements or functional product consortia.
Research

A New Way To Improve Gut Health: Probiotic Consortia With Bifidobacterium And Propionibacterium Strains

May 26, 2022
Dutch Study Links Diet Quality With IBD And IBS Symptoms
Research

Dutch Study Links Diet Quality With IBD And IBS Symptoms

May 24, 2022
Thailand Study Recommends Low FODMAP Diet For Patients Suffering From Gastric Reflux And Irritable Bowel Syndrome
Research

Thailand Study Recommends Low FODMAP Diet For Patients Suffering From Gastric Reflux And Irritable Bowel Syndrome

May 24, 2022
Next Post
Predictive Markers For Microbiota In Gut Found In PIBD Patients On IFX Treatment

Predictive Markers For Microbiota In Gut Found In PIBD Patients On IFX Treatment

Inflammatory Bowel Disease Does Not Increase Risk Of Breakthrough Covid-19 Cases In Fully Vaccinated Patients

Inflammatory Bowel Disease Does Not Increase Risk Of Breakthrough Covid-19 Cases In Fully Vaccinated Patients

The Low FODMAP Diet Should Be The First Line Of Defense For IBS Patients

The Low FODMAP Diet Should Be The First Line Of Defense For IBS Patients

Follow Us

  • 9.7k Followers

Recommended

The Inspiring story of young Indian Entrepreneur Mrinal Mishra

1 year ago
Kite365: The Rise of Self-made Young Entrepreneur Mohayudeen Lakhani

Kite365: The Rise of Self-made Young Entrepreneur Mohayudeen Lakhani

1 year ago
With 4,01,000 new permanent residents, Canada meets its immigration target for 2021.

With 4,01,000 new permanent residents, Canada meets its immigration target for 2021.

5 months ago
Former President Park Geun-hye, who was imprisoned for corruption, will be granted a special pardon by South Korea.

Former President Park Geun-hye, who was imprisoned for corruption, will be granted a special pardon by South Korea.

5 months ago

Instagram

    Go to the Customizer > JNews : Social, Like & View > Instagram Feed Setting, to connect your Instagram account.

Categories

  • General
  • News
  • Research

Topics

antibiotics capsaicin COVID Crohn's Disease fatigue Finocontrol FODMAP german ambulance german news gluten-free Gopal Khilwani gut gut bacteria gut microbiome gut microbiota Harsh Sharma Harsh Sharma Max health healthy diet IBD IBS IBS diet inflammation inflammatory bowel disease irritable bowel syndrome Jaora Karishma Kar low FODMAP diet Max microbiota Omicron pension peppermint oil Priyanshu Behera probiotics prototype lickable TV screen russian pension SIBO sports Taste the TV (TTTV) Tiktok treatment ukraine news United States Yash Shukla
No Result
View All Result
https://casadesante.com https://casadesante.com https://casadesante.com

Highlights

IBD Patients Report Relatively Greater Fatigue; Anxiety & Steroid Use Possible Links

Standardized Microbiome Therapies In Recurrent C. difficile: Promising Alternatives To Fecal Microbiota Transplantation

Data From Clinical Claims Suggests A Possible Association Between Antibiotic Use And Inflammatory Bowel Disease

Clinical Study Supports North Atlantic Consensus Recommendations For Diagnosing SIBO & Carbohydrate Malabsorption Via Breath Testing

French Real-World Study Upholds Benefits Of Bifidobacterium longum 35624 In Severe IBS

Study Shows IBD Patients Have Altered Gut Microbe Composition Even In Remission Phase

Trending

A research paper was published in the Brazilian Journal of Biology, titled "Using Bifidobacterium and Propionibacterium Strains in Probiotic Consortia to Normalize the Gastrointestinal Tract." Based on expert opinions in the study, the microorganisms Bifidobacterium and Propionibacterium genera qualities can be preserved and encapsulated. This research backs up expert suggestions with clinical evidence, proving that the experts were correct. The gut microflora is responsible for regulating the body's activities and maintaining its health. Diabetes, obesity, inflammation, atherosclerosis, and other chronic diseases are due to dysbiosis. In the 2024 recommendations, experts recommended probiotics for living microorganisms that benefit the microflora and improve the health of the host organism helping prevent these diseases. Lactic acid bacteria from the Bifidobacterium and Propionibacterium genera are the frequent probiotics recommended. Bifidobacterium adolescentis-1909, Bifidobacterium longum infantis-1912, Propionibacterium jensenii B-6085, Propionibacterium freudenreichii -11921, Propionibacterium thoenii -6082, and Propionibacterium acidipropionici-5723 were examined for their probiotic characteristics in the study. This study was conducted in the Laboratory for Bio testing Natural Nutraceuticals at Kemerovo State University (Russia). The study used collection strains of the lactic acid bacteria Bifidobacterium adolescentis АС-1909, Bifidobacterium longum infantis АС-1912, Propionibacterium jensenii В-6085, Propionibacterium freudenreichiiВ-11921, Propionibacterium thoenii В-6082, and Propionibacterium acidipropionici В-5723. Lactic acid cultures were tested for antibacterial activity against the test cultures Salmonella enterica ATCC 14028, Staphylococcus aureusATCC 25923, Pseudomonas aeruginosa B6643, Proteus Vulgaris ATCC 63, and Listeria monocytogenes ATCC 7644. Additionally, the antibiotic resistance of lactic acid cultures was tested using the disk diffusion method. Bifidobacterium adolescentis-1909, Propionibacterium jensenii B-6085, and Propionibacterium thoenii 6082 showed moderate antibacterial activities against all test cultures. According to research, some Propionibacterium and Bifidobacterium strains, or their consortia, could be employed as probiotic cultures in dietary supplements or functional foods to prevent various chronic diseases like IBS. Why is this study important for patients with IBS Symptoms Although IBS is bothersome and inconvenient, it does not increase the chance of developing other health problems. However, the success of the treatment depends on what grade of IBS it is and how it is addressed. Bifidobacterium bacteria are particularly significant compared with other gut microbiota in probiotic cultures. Probiotics have a favorable effect in four ways. First, they produce antimicrobial compounds. Second, they are hostile to pathogenic and opportunistic strains. They also adhere to epithelial cells (cells of intestinal walls), posing a competitive threat to disease-causing bacteria. Finally, they inhibit the production of metabolites by pathogenic bacteria and cancer cells. What is the Key Takeaway from this Study Large doses of probiotics that contain these bacteria in dietary supplements or functional fermented milk products can stimulate their proliferation in the large intestine. The development of functional foods containing probiotics, particularly Bifidobacterium strains, is driven by the increased demand for health-beneficial foods. However, Propionibacterium 'dairy' strains have recently gained popularity. As a result, probiotic consortia of these species can be established to normalize the gastrointestinal microbiota's function. To preserve their quality, these microorganisms can be encapsulated (immobilized). All the strains can be employed to form various dietary supplements or functional product consortia.
Research

A New Way To Improve Gut Health: Probiotic Consortia With Bifidobacterium And Propionibacterium Strains

by Editorial Team
May 26, 2022
0

Medically reviewed by Onikepe Adegbola, MD, PhD  Image from Unsplash A research paper was published in the...

Dutch Study Links Diet Quality With IBD And IBS Symptoms

Dutch Study Links Diet Quality With IBD And IBS Symptoms

May 24, 2022
Thailand Study Recommends Low FODMAP Diet For Patients Suffering From Gastric Reflux And Irritable Bowel Syndrome

Thailand Study Recommends Low FODMAP Diet For Patients Suffering From Gastric Reflux And Irritable Bowel Syndrome

May 24, 2022
IBD Patients Report Relatively Greater Fatigue; Anxiety & Steroid Use Possible Links

IBD Patients Report Relatively Greater Fatigue; Anxiety & Steroid Use Possible Links

May 24, 2022
Standardized Microbiome Therapies In Recurrent C. difficile: Promising Alternatives To Fecal Microbiota Transplantation

Standardized Microbiome Therapies In Recurrent C. difficile: Promising Alternatives To Fecal Microbiota Transplantation

May 24, 2022
Dope Entrepreneurs

Dope Entrepreneurs is the hub for all dope gut health related content. We are a groundbreaking news publication dedicated to gut health. We cover gut health research, entrepreneurship, startups and the latest trends in gut health. We serve a growing segment of patients, entrepreneurs and investors who want to learn more about gut health, the disruption and market potential in this field, and how they can benefit from the latest advances in gut health. Dope entrepreneurs is led by Onikepe Adegbola, MD PhD DipIBLM, physician, scientist, and gut health entrepreneur.

Categories

  • Research
  • News
  • Articles
  • Reviews
  • About Us
  • Contact Us
  • Privacy Policy
  • Terms And Conditions


© 2022 Dope Entrepreneurs

No Result
View All Result
  • Research
  • News
  • Interviews
  • Articles
  • Reviews

© 2022 Dope Entrepreneurs

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist